- #1
TranscedentKid
- 27
- 0
Why is gold un-reactive enough to be used as nanoparticles?
Why do cells preform endocytosis upon detection of the gold delivery system? What are the chemical receptors active?
Why is does it cause less genetic damage than doing it virally?
Is this system partly designed to change the DNA of stem cells so that the physiology of the organism changes?
Here is a link
https://www.genengnews.com/gen-news...chnologies-wont-lead-designer-babies/']crispr-nanoparticles-repair-duchenne-muscular-dystrophy-gene/81255009?q=murthy[/URL]
Why do cells preform endocytosis upon detection of the gold delivery system? What are the chemical receptors active?
Why is does it cause less genetic damage than doing it virally?
Is this system partly designed to change the DNA of stem cells so that the physiology of the organism changes?
Here is a link
https://www.genengnews.com/gen-news...chnologies-wont-lead-designer-babies/']crispr-nanoparticles-repair-duchenne-muscular-dystrophy-gene/81255009?q=murthy[/URL]
Scientists have developed a gold nanoparticle technology for delivering the CRISPR/Cas9 gene-editing system to cells that, when tested in the mdx mouse model of Duchenne muscular dystrophy (DMD), repaired the faulty DMD gene, leading to improved strength and agility and reduced fibrosis. Professor Niren Murthy, Ph.D., the University of California, Berkeley (UC Berkeley) researcher who led development of the CRISPR-Gold platform, suggested to GEN that human clinical gene-editing trials using the system could feasibly start within the next few years.
CRISPR-Gold uses gold nanoparticles to encapsulate all of the elements needed for CRISPR/Cas9 gene editing and deliver them directly to cells. Initial tests in mice achieved levels of gene correction that could demonstrate significant clinical benefit if they can be reproduced in humans, professor Murthy told GEN. “We think a clinical trial for therapeutic gene editing with CRISPR-Gold and its derivatives could happen within 5 years.” However, he added, its not clear whether initial trials will be in DMD, or another disease. “DMD is a very compelling first clinical application of the CRISPR-Gold technology, however there are several others, and it is still too soon to say what the first clinical application will be.”
Last edited by a moderator: